This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
microRNA EXPRESSION PROFILES IDENTIFY SUBTYPES OF MANTLE CELL
LYMPHOMA WITH DIFFERENT CLINICOBIOLOGICAL CHARACTERISTICS
Alba Navarro1, Guillem Clot1, Miriam Prieto1, Cristina Royo1, Maria Carmela Vegliante1,
Virginia Amador1, Elena Hartmann2, Itziar Salaverria1, Sílvia Beà1, Jose Ignacio Martín-Subero3,
Andreas Rosenwald2, German Ott4, Adrian Wiestner5, Wyndham H. Wilson6, Elías Campo1,
Luis Hernández1
1Department of Pathology, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i
Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; 2Institute of Pathology,
University of Würzburg, Germany; 3Department of Pathology, Pharmacology and Microbiology,
Universitat of Barcelona, Barcelona, Spain; 4Department of Clinical Pathology, Robert Bosch
Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart,
Germany; 5Hematology Branch, NHLBI, NIH, Bethesda, MD, USA. 6Center for Cancer
Research, National Cancer Institute, NIH, Bethesda, MD.
Running title: miR expression profiles in mantle cell lymphoma
Abstract count: 250 words
Text count: 4206 words main text
Corresponding author: Luis Hernández, IDIBAPS, Edifici Centre Esther Koplowitz (CEK),
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
References 1. Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional
gene regulation. Oncogene 2006;25:6163-9.
2. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-73.
3. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005;15:563-8.
4. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
5. Huppi K, Volfovsky N, Mackiewicz M, Runfola T, Jones TL, Martin SE et al. MicroRNAs and genomic instability. Semin Cancer Biol 2007;17:65-73.
6. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006;25:6202-10.
7. Fabbri M, Croce CM. Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol 2011;18:266-72.
8. Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84:2726-32.
9. Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Bea S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 2011;21:322-34.
10. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-62.
11. Di Lisio L, Gomez-Lopez G, Sanchez-Beato M, Gomez-Abad C, Rodriguez ME, Villuendas R et al. Mantle cell lymphoma: transcriptional regulation by microRNAs. Leukemia 2010;24:1335-42.
12. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010;115:2630-9.
13. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408-18.
14. Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biological and clinical features. Cancer Res 2012;(In Press).
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
15. Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011;96:1121-7.
16. Royo C, Navarro A, Clot G, Salaverria I, Gine E, Jares P et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012;26:1895-8.
17. Rule SA, Poplar S, Evans PA, O'Connor SJ, Owen RG. Indolent mantle-cell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation. J Clin Oncol 2011;29:e437-e439.
18. Iqbal J, Shen Y, Liu Y, Fu K, Jaffe ES, Liu C et al. Genome-wide MicroRNA profiling of mantle cell lymphoma reveal a distinct subgroup with poor prognosis. Blood 2012;119:4939-48.
19. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-317.
20. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010;26:1572-3.
21. Monti S, Tamayo P, Mesirov J, Golub T. Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data. Machine learning 2003;52:91-118.
22. Camacho E, Hernandez L, Hernandez S, Tort F, Bellosillo B, Bea S et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 2002;99:238-44.
23. Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K et al. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011;30:1470-80.
24. Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B et al. Phospho-DeltaNp63alpha is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ 2011;18:1220-30.
25. Basso K, Klein U, Niu H, Stolovitzky GA, Tu Y, Califano A et al. Tracking CD40 signaling during germinal center development. Blood 2004;104:4088-96.
26. Reimand J, Arak T, Vilo J. g:Profiler--a web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res 2011;39:W307-W315.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
27. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-97.
28. Chen F, Hu SJ. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol 2012;26:79-86.
29. Hartmann E, Fernandez V, Moreno V, Valls J, Hernandez L, Bosch F et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008;26:4966-72.
30. Kienle D, Katzenberger T, Ott G, Saupe D, Benner A, Kohlhammer H et al. Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. J Clin Oncol 2007;25:2770-7.
31. Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Chang I et al. MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. Carcinogenesis 2012;33:294-300.
32. Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X et al. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 2009;80:268-73.
33. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 2010;17:236-45.
34. Navarro A, Bea S, Fernandez V, Prieto M, Salaverria I, Jares P et al. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res 2009;69:7071-8.
35. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000;1:179-86.
36. Han BW, Feng DD, Li ZG, Luo XQ, Zhang H, Li XJ et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet 2011;20:4903-15.
37. Monk CE, Hutvagner G, Arthur JS. Regulation of miRNA transcription in macrophages in response to Candida albicans. PLoS ONE 2010;5:e13669.
38. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476:298-303.
39. Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003;101:4975-81.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077
Published OnlineFirst May 2, 2013.Clin Cancer Res Alba Navarro, Guillem Clot, Miriam Prieto, et al. CLINICOBIOLOGICAL CHARACTERISTICSMANTLE CELL LYMPHOMA WITH DIFFERENT microRNA EXPRESSION PROFILES IDENTIFY SUBTYPES OF
Updated version
10.1158/1078-0432.CCR-12-3077doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2013/05/02/1078-0432.CCR-12-3077To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 2, 2013; DOI: 10.1158/1078-0432.CCR-12-3077